{"schema_version":"secwatch.filing_event.v1","accession":"0001185185-24-000654","form_type":"8-K/A","ticker":"BHIC","cik":"0001784440","company_name":"BioScience Health Innovations, Inc.","filed_at":"2024-06-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.086814+00:00","generated_at":"2026-06-01T02:14:36.936063+00:00","sec_items":["1.01","2.01","5.03","9.01","4.01","3.02","5.02","5.06"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Nowtransit completes reverse merger with Best Labs; issues 34M shares (85.4%) for supplement business","bullets":["Issued 34,371,100 shares (85.39% of post-closing shares) to Best Labs shareholders for all of Best's shares; deal closed March 10, 2023.","Company exited online delivery business; now markets Be On-Guard mouth spray, nasal spray, surface cleaner, brain support supplements, and methylene blue products.","Zero employees as of March 13, 2023; supply chain managed by Ageless Holdings LLC (CEO is managing member).","Filing addresses shell status; company remains OTC Pink voluntary filer, subject to penny stock rules and limited liquidity.","Holds provisional patent 63/560,474 for methylthioninium salt compositions; plans to file PCT application by March 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-24-000654","json":"https://secwatch.observer/filing/0001185185-24-000654.json","markdown":"https://secwatch.observer/filing/0001185185-24-000654.md","text":"https://secwatch.observer/filing/0001185185-24-000654.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1784440/000118518524000654/0001185185-24-000654-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1784440/000118518524000654/nowtransit20240625_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:14:36.936063+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"35e00cd76a","claim":"Darren Lopez was appointed as Director at BioScience Health Innovations, Inc..","evidence_excerpt":"Darren Lopez and John Chymboryk were appointed to serve on the Board of Directors with Justin Earl.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1784440/000118518524000654/0001185185-24-000654-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"706edba3cf","claim":"Justin Earl resigned as Chief Executive Officer at BioScience Health Innovations, Inc..","evidence_excerpt":"Justin Earl tendered his resignation as the sole officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1784440/000118518524000654/0001185185-24-000654-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"857994cd78","claim":"John Chymboryk was appointed as Director at BioScience Health Innovations, Inc..","evidence_excerpt":"Darren Lopez and John Chymboryk were appointed to serve on the Board of Directors with Justin Earl.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1784440/000118518524000654/0001185185-24-000654-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"bb00913206","claim":"Darren Lopez was appointed as Chief Executive Officer at BioScience Health Innovations, Inc..","evidence_excerpt":"Darren López was appointed as the Chief Executive Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1784440/000118518524000654/0001185185-24-000654-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"4f00d8a3ee69d7ec3637208e5e3b630aa2577a4d","claim":"BioScience Health Innovations, Inc. completed an acquisition involving Best Labs, Inc. for 34,371,100 shares of the Company’s common stock, representing approximately 85.39% of the issued and outstanding shares (closed 2023-03-10).","evidence_excerpt":"2023 (the “ Closing ”). As a result of the Exchange Agreement Best became the wholly-owned subsidiary of the Company. Upon the Closing, the Company issued the Best shareholders 34,371,100 shares of the Company’s common stock, representing approximately 85.39% of the issued and outstanding shares of the Company’s common stock following Closing, in exchange for all","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1784440/000118518524000654/0001185185-24-000654-index.htm","confidence":0.98,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Best Labs, Inc."},{"label":"Consideration","value":"34,371,100 shares of the Company’s common stock, representing approximately 85.39% of the issued and outstanding shares"},{"label":"Closing","value":"2023-03-10"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}